Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zhengqing Fengtongning acupoint injection for bone metastasis cancer pain in lung and prostate cancer
ChiCTR2200063058Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Hunan University of Chinese Medicine
- Start
- Jul 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of sinomenine in bronchial carcinoma and prostate cancer (PCa) (6 arms), sponsored by First Affiliated Hospital of Hunan University of Chinese Medicine. Primary endpoint: Effective pain relief. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
sinomenine
03
Conditions
bronchial carcinomaprostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2200063058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063058.